argenx SE (ARGX)

Market Cap	33.86B
Revenue (ttm)	2.64B
Net Income (ttm)	1.06B
Shares Out	60.98M
EPS (ttm)	15.94
PE Ratio	31.82
Forward PE	38.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	476,771
Open	538.50
Previous Close	549.65
Day's Range	535.50 - 560.79
52-Week Range	352.77 - 678.21
Beta	0.17
Analysts	Strong Buy
Price Target	698.22 (+24.78%)
Earnings Date	May 8, 2025

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,599
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://argenx.com

Analyst Forecast

According to 20 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $698.22, which is an increase of 24.78% from the latest price.

Price Target

$698.22

(24.78% upside)

Analyst Consensus: Strong Buy